1,722,362 research outputs found
Laboratory Analysis of a Piston-Actuated Pressure-Reducing Valve under Low Flow Conditions
No full textThe effectiveness of pressure-reducing valves (PRVs) for optimal pressure management of water distribution networks (WDNs) is proven, but problems and operational limitations have been highlighted by some recent experiences. In this study, we analyse the functioning of a piston-actuated pressure-reducing valve (PA-PRV) with a mechanical pilot which is subjected to low-flow regimes, a condition that is often observed in real water distribution networks. The analyses were carried out by means of laboratory tests featuring two sets of experiments, i.e., (a) by testing the behaviour of the PRV when a pre-established initial value and subsequent variation of flow rate occurs in the system and (b) by testing the PRV against a temporal series of flow rates observed at the inlet section of a real district metered area. The first set of tests showed that the PA-PRV tends not to maintain pressure at the imposed set-point and exhibits an unstable behaviour characterised by significant pressure oscillations under some flow rate conditions. The second set of laboratory tests showed that the anomalous behaviour identified in the first set of tests can occur under ordinary operational conditions of a network
Acquired von Willebrand syndrome: An update
No full textAcquired von Willebrand syndrome (aVWS) is a rare bleeding disorder with laboratory findings similar to those for congenital von Willebrand disease (VWD). However, unlike congenital VWD, it arises in individuals with no personal or family history of bleeding. aVWS occurs in association with a variety of underlying disorders, most frequently in lymphoproliferative disorders, myeloproliferative disorders, and cardiovascular diseases. Through an analysis of the more recent literature data, the pathophysiology and the clinical, laboratory, and therapeutic aspects of this syndrome are concisely reported in this review. © 2006 Wiley-Liss, Inc
How I treat acquired factor VIII inhibitors.
No full textAcquired hemophilia A is a rare bleeding diathesis caused by autoantibodies directed against clotting factor VII and associated with an increased morbidity and mortality. This autoimmune disorder most commonly occurs in the elderly. Although it may be associated with several underlying pathologies, up to 50% of reported cases remain idiopathic. In contrast with congenital hemophilia, which is commonly characterized by hemarthroses, hemorrhages in patients with acquired hemophilia involve most frequently soft tissues. The 2 treatment priorities are to arrest the acute bleeding and to eradicate the factor VIII autoantibody. Acute bleeding episodes in patients with low-titer inhibitors can be treated using human factor VIIIconcentrates, whereas factor VIII bypassing agents, such as activated prothrombin complex concentrates or recombinant activated factor VII, are effective for the treatment of those with hightiter inhibitors. An analysis of the literature shows that the most effective first-line treatment for the eradication of factor VIII autoantibodies is the combination of steroids and cyclophosphamide. However, there is increasing evidence on the effectiveness of other treatment approaches, such as immune tolerance regimens and rituximab. If confirmed by large controlled studies, these innovative therapies might become a valid option for long-term eradication of factor VIII inhibitors. © 2008 by The American Society of Hematology
Von Willebrand factor-containing factor VIII concentrates and inhibitors in haemophilia A. A critical literature review.
No full textThe development of inhibitors that neutralise the function of factor VIII (FVIII) is currently not only the most challenging complication associated with the treatment of haemophilia A but it also increases the disease-related morbidity as bleeding episodes do not respond to standard therapy. The main short-term goal of the treatment of inhibitor patients is to control bleeding episodes while the long-term one is to permanently eradicate the inhibitor by immune tolerance induction, particularly in the case of high-titer antibodies. Due to some in vitro studies and clinical observations, some investigators have suggested that FVIII concentrates containing von Willebrand factor (VWF) may be less immunogenic than high-purity or recombinant FVIII products. It has also been suggested that success rates for immune tolerance induction are higher when plasma-derived FVIII products are used. The currently available data from laboratory and clinical studies on the role of VWF in inhibitor development and eradication in haemophilia A is critically analysed in this review. As a result, we have not found definitive evidence supporting a role for product type on inhibitor incidence and inhibitor eradication in haemophilia A patients. © Schattauer 2010
A robust approach based on time variable trigger levels for pump control
No full textAn approach for the control of a pumping plant feeding a tank at the inlet of a water distribution system is presented. The approach is aimed at minimizing the energy costs by maximizing pumping during off-peak electricity tariff periods. It is based on trigger levels which are variable during the day according to a prefixed pattern in order to ensure that the water level in the elevated tank is at its minimum and maximum values at the end of the peak and off-peak tariff periods, respectively. The pattern of the trigger levels is defined by solving a multi-objective problem aimed at minimizing the energy costs and the number of pump switches.
The approach was applied to a couple of real cases with a single tank. The approach was compared with other methodologies typically used for pump control, i.e. fixed trigger levels and pump scheduling. The results show for the two particular cases that the proposed approach achieves energy costs that are lower than those obtainable by using fixed trigger levels, and comparable with those obtainable by using pump scheduling. This is based on achieving a similar number of pump switches
Recombinant activated factor VII: mechanisms of action and current indications.
No full textRecombinant activated factor VII: mechanisms of action and current indications
- …
